Novartis AG

Company Profile

Novartis AG had its IPO on under the ticker symbol NVSEF.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Novartis AG has a staff strength of 103,000 employees.

Stock update

Shares of Novartis AG opened at $96.2 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $96.2 - $96.2, and closed at $96.2.

This is a -3.32% slip from the previous day's closing price.

A total volume of 528 shares were traded at the close of the day’s session.

In the last one week, shares of Novartis AG have slipped by -5.42%.

Novartis AG's Key Ratios

Novartis AG has a market cap of $198.97 billion, indicating a price to book ratio of 3.2152 and a price to sales ratio of 3.8151.

In the last 12-months Novartis AG’s revenue was $53.07 billion with a gross profit of $36.74 billion and an EBITDA of $20.03 billion. The EBITDA ratio measures Novartis AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Novartis AG’s operating margin was 27.69% while its return on assets stood at 7.86% with a return of equity of 13.32%.

In Q2, Novartis AG’s quarterly earnings growth was a positive 44.2% while revenue growth was a positive 6.5%.

Novartis AG’s PE and PEG Ratio

Forward PE

14.2857

Trailing PE

26.7222

PEG

5.6678

Its diluted EPS in the last 12-months stands at $3.6 per share while it has a forward price to earnings multiple of 14.2857 and a PEG multiple of 5.6678. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novartis AG’s profitability.

Novartis AG stock is trading at a EV to sales ratio of 3.9682 and a EV to EBITDA ratio of 6.6563. Its price to sales ratio in the trailing 12-months stood at 3.8151.

Novartis AG stock pays annual dividends of $3.461 per share, indicating a yield of 3.45% and a payout ratio of 51.22%.

Balance sheet and cash flow metrics

Total Assets

$110.98 billion

Total Liabilities

$31.91 billion

Operating Cash Flow

$0

Capital Expenditure

$996 million

Dividend Payout Ratio

51.22%

Novartis AG ended 2024 with $110.98 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $110.98 billion while shareholder equity stood at $51.85 billion.

Novartis AG ended 2024 with $0 in deferred long-term liabilities, $31.91 billion in other current liabilities, 842000000.00 in common stock, $0 in retained earnings and $29.52 billion in goodwill. Its cash balance stood at $10.89 billion and cash and short-term investments were $11.17 billion. The company’s total short-term debt was $8,536,000,000 while long-term debt stood at $18.26 billion.

Novartis AG’s total current assets stands at $33.49 billion while long-term investments were $2.43 billion and short-term investments were $289.00 million. Its net receivables were $9.54 billion compared to accounts payable of $5.35 billion and inventory worth $8.23 billion.

In 2024, Novartis AG's operating cash flow was $0 while its capital expenditure stood at $996 million.

Comparatively, Novartis AG paid $0.51 in dividends in 2024.

Other key metrics

Current Trading Price

$96.2

52-Week High

$106.5

52-Week Low

$70.0308

Analyst Target Price

$

Novartis AG stock is currently trading at $96.2 per share. It touched a 52-week high of $106.5 and a 52-week low of $106.5. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $101.15 and 200-day moving average was $91.95 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 394.7% of the company’s stock are held by insiders while 3607.8% are held by institutions.